Patents by Inventor Jin Koung KIM

Jin Koung KIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS COMPRISING 5-CHOLESTEN-3, 25-DIOL, 3-SULFATE (25HC3S) OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND AT LEAST ONE CYCLIC OLIGOSACCHARIDE
    Publication number: 20230047788
    Abstract: Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.
    Type: Application
    Filed: June 28, 2022
    Publication date: February 16, 2023
    Inventors: Shunlin Ren, Leyuan Xu, Yanxia Ning, Jin Koung Kim, WeiQi Lin, Andrew R. Miksztal, Hongwei Wu, Min L. Lee
  • Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
    Patent number: 11406646
    Abstract: Compositions comprising 5-cholesten-3,25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: August 9, 2022
    Assignees: Virginia Commonwealth University, Durect Corporation, The United States Government as Represented by The Department of Veterans Affairs
    Inventors: Shunlin Ren, Leyuan Xu, Yanxia Ning, Jin Koung Kim, WeiQi Lin, Andrew R. Miksztal, Hongwei Wu, Min L. Lee
  • COMPOSITIONS COMPRISING 5-CHOLESTEN-3, 25-DIOL, 3-SULFATE (25HC3S) OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND AT LEAST ONE CYCLIC OLIGOSACCHARIDE
    Publication number: 20210169898
    Abstract: Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.
    Type: Application
    Filed: November 10, 2020
    Publication date: June 10, 2021
    Inventors: Shunlin Ren, Leyuan Xu, Yanxia Ning, Jin Koung Kim, WeiQi Lin, Mee Jean Kim, Andrew R. Miksztal, Hongwei Wu, Min L. Lee, Wilma Tamraz
  • OXYGENATED CHOLESTEROL SULFATES FOR THERAPY OF DISORDERS CAUSED BY AT LEAST ONE OF ATTENUATED LEPTIN ACTIVITY AND A LIPID STORAGE DISORDER
    Publication number: 20210161913
    Abstract: Methods and compositions are provided for the prevention and/or treatment of symptoms associated with lipid accumulation disorders caused by attenuated leptin activity and by lipid storage disorders. The methods involve administering at least one oxygenated cholesterol sulfate (OCS) to a subject with the disorder. The disorder may be acquired or congenital (hereditary).
    Type: Application
    Filed: November 2, 2020
    Publication date: June 3, 2021
    Inventors: Shunlin Ren, Jin Koung Kim
  • OXYGENATED CHOLESTEROL SULFATES FOR THERAPY OF DISORDERS CAUSED BY AT LEAST ONE OF ATTENUATED LEPTIN ACTIVITY AND A LIPID STORAGE DISORDER
    Publication number: 20200138831
    Abstract: Methods and compositions are provided for the prevention and/or treatment of symptoms associated with lipid accumulation disorders caused by attenuated leptin activity and by lipid storage disorders. The methods involve administering at least one oxygenated cholesterol sulfate (OCS) to a subject with the disorder. The disorder may be acquired or congenital (hereditary).
    Type: Application
    Filed: October 4, 2019
    Publication date: May 7, 2020
    Inventors: Shunlin REN, Jin Koung KIM
  • COMPOSITIONS COMPRISING 5-CHOLESTEN-3, 25-DIOL, 3-SULFATE (25HC3S) OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND AT LEAST ONE CYCLIC OLIGOSACCHARIDE
    Publication number: 20190269695
    Abstract: Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide, e.g., a cyclodextrin (CD), are provided. The compositions may be used to prevent and/or treat a variety of diseases and conditions, including organ failure (e.g. acute liver failure), high cholesterol/high lipids, and various inflammatory diseases and conditions.
    Type: Application
    Filed: August 1, 2017
    Publication date: September 5, 2019
    Inventors: Shunlin Ren, Leyuan Xu, Yanxia Ning, Jin Koung Kim, WeiQi Lin, Mee Jean Kim, Andrew R. Miksztal, Hongwei Wu, Min L. Lee, Wilma Tamraz
  • OXYGENATED CHOLESTEROL SULFATES FOR THERAPY OF DISORDERS CAUSED BY AT LEAST ONE OF ATTENUATED LEPTIN ACTIVITY AND A LIPID STORAGE DISORDER
    Publication number: 20190083509
    Abstract: Methods and compositions are provided for the prevention and/or treatment of symptoms associated with lipid accumulation disorders caused by attenuated leptin activity and by lipid storage disorders. The methods involve administering at least one oxygenated cholesterol sulfate (OCS) to a subject with the disorder. The disorder may be acquired or congenital (hereditary).
    Type: Application
    Filed: August 22, 2018
    Publication date: March 21, 2019
    Inventors: Shunlin REN, Jin Koung KIM
  • OXYGENATED CHOLESTEROL SULFATES FOR THERAPY OF DISORDERS CAUSED BY AT LEAST ONE OF ATTENUATED LEPTIN ACTIVITY AND A LIPID STORAGE DISORDER
    Publication number: 20170252355
    Abstract: Methods and compositions are provided for the prevention and/or treatment of symptoms associated with lipid accumulation disorders caused by attenuated leptin activity and by lipid storage disorders. The methods involve administering at least one oxygenated cholesterol sulfate (OCS) to a subject with the disorder. The disorder may be acquired or congenital (hereditary).
    Type: Application
    Filed: October 13, 2015
    Publication date: September 7, 2017
    Inventors: Shunlin REN, Jin Koung KIM